CONSTRUCTION Oct2021 GineersNow - Delta Variant Slowing Down Construction Recovery

N E W S
S T O R I E S
How Brii Biosciences COVID Has Accelerated
Announces
Seattle Co Develops Rapid
Positive Automation Data in from Automotive the Phase
Fingerprinting For Covid-19
3 ACTIV-2 Warehouses Trial Evaluating
Variants
Combination BRII-196 and
The COVID-19 pandemic has forever
changed the warehousing industry. The
spread of infectious disease puts workers
at risk, but the work must go on. Instead of having
humans move packages and manufacture
goods by hand, facilities are using machines
to reduce the spread of germs that can lead
to infection. That’s why industrial analysts
believe “the pandemic displaced more workers
The
in automatable occupations,
monoclonal
putting them at a
greater
antibody
risk of being
combination
permanently automated.”
therapy reduced the
The automotive
combined
industry
endpoint
is already known for its
of
use
hospitalizations
of automation, and
and
the
death
recent healthcare
by
crisis
78%
will
over
only
placebo
accelerate
in
this
837
trend. Find out
COVID-19
what this means
patients
for
at
the
high
automotive
risk
industry at
of
large.
clinical progression.
BRII-198 in Non-Hospitalized
COVID-19 Patients
would have if they had used human workers.
Automation reduces the need for employee
participation and training, so managers could
start producing new vehicles with little help
from the outside world.
With machines doing the bulk of the work,
managers didn’t have to worry about new
These
Fewer
data
Workers
demonstrate
on Site
that
outbreaks disrupting their operations. If
high-risk outpatients may benefit
someone came to work infected with COVID-19,
from
Running
combination
a business in
BRII-196/
the age of COVID-19 can they would’ve had to close down the facility,
BRII-198
be a challenge,
therapy
if
up
not
to
impossible.
10 days
Many states disinfect nearly every surface and ask their
following
Fand countries
symptom
have
onset.
imposed strict lockdowns on
non-essential
irst-Ever Technology
businesses.
Receives
Even if some
NIH
196/BRII-198”), facilities
Grant offers
workers
the potential
to quarantine
to detect
to make
the emergence
sure they were
of
demonstrated in both hospitalizations (12
Brii
could
to Speed
Biosciences
stay open
Up Availability
throughout
of
Limited (“Brii
the
Testing
pandemic, a statistically the
novel
not infected
variants.
with
The
the
entire
virus.
test not only can be
significant active vs. 45 placebo) and
Bio”
cost of
or
keeping
the “Company”,
workers safe
stock
can reduction be prohibitive
accomplished
For many
in
companies,
2 hours, but also
automation
will not require
meant
of 78%, relative deaths (1 active vs. 9 placebo)
code:
for
ID Genomics
some
2137.HK)
corporations.
(IDG), a Seattle-based
a multi-national
Employers
company,
risk must ([95% now
expensive
stability and
instrumentation,
predictability
and
in
can
an
be
increasingly
rapidly
CI]: 0.22 [0.05, was observed. Additional
company
invest
has invented
in face
a
developing
masks,
dipstick-based,
innovative
gloves, disinfectant
rapid test for
0.86], p<0.00001 and
deployed
unpredictable
across
world.
epidemiological surveillance
(nominal, subgroup analysis may further
therapies
proper
simultaneous
ventilation
identification
for diseases
to limit the
of
with
spread
a large
one-sided)) of
number
airborne
labs globally.
in the combined delineate the clinical benefits
significant
particles
of genetic
that
variants
unmet
can lead
of
to
SARS-CoV-2
medical
infection.
and has
Increasing Efficiency
endpoint of hospitalization and of early (≤5 days) versus late
just received a National Institutes of Health “The recent explosive rise in various SARSneed
and large public health death compared with placebo (6-10 days) treatment with
burden,
To
(NIH)
get
grant
around
to expedite
today
these
announced
new
bringing
expenses,
this test
in 837 many
to CoV-2
Automation
mutants,
was
especially
known
those
for its
with
benefits
changes
long
non-hospitalized
before the rise of BRII-196/BRII-198
COVID-19. Industry following experts
that
companies
market.
its SARS-CoV-2
doubled down
(virus
on
that
their COVID-19 investments
in the Spike protein – the main target of vaccines
patients believe at companies high symptom that employ onset, providing the latest
causes
in automation.
COVID-19)
Replacing
neutralizing
human risk workers of clinical with
– is of very significant concern due to the ability
technology progression. effectively unique insight are 10 to inform times realworld
those treatment that do decisions. not. Machines
more
monoclonal
machines
The test will
limits
‘fingerprint’
the number
at once
antibody
of In personnel
all currently
this interim on
of the mutated variants to escape protective
productive analysis than of
combination
site
known
which
COVID-19
reduces
variants
therapy,
the
BRII-196/
chances
of concern
the of ACTIV-2 infection.
or antibodies, becoming more transmissible and/
trial can based usually on complete a task in a fraction of the
BRII-198
Having
interest,
fewer
including
(“combination
workers
Alpha,
on
Beta,
BRIIsite
partial has
Gamma,
helped
or virulent,” said the Principal Investigator
follow-up time of it the would 837 take The a BRII-196/BRII-198 human worker with arm less of
these
Delta, Delta-plus,
companies
Epsilon,
rebound
Lambda,
faster participants, than
etc, and
they
Evgeni Sokurenko, MD, PhD, a Founder
room a reduction for error. the Phase 2/3 ACTIV-2 platform
72